title: [Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma].
abstract: We measured rituximab concentrations in the cerebrospinal fluid (CSF) in 2 patients with diffuse large B-cell lymphoma in whom central nervous system (CNS) invasion had developed. They received rituximab intravenously following irradiation therapy (patient no.1) or along with chemotherapy (patient no.2). The rituximab concentrations in the CSF were considered to be very low (0.2-0.6 microg/ml), and could not be increased significantly by serial intravenous administrations of rituximab. The lymphoma relapsed in patient no.1, and the combined therapy was not effective in patient no.2. An alternative approach such as intrathecal administration of rituximab could be anticipated as a new therapeutic strategy for CNS lymphoma.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Tokai University School of Medicine.
authors.forename: Ako
authors.initials: A
authors.lastname: Kikuchi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kawada
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Iwaki
authors.forename: Shinichirou
authors.initials: S
authors.lastname: Machida
authors.forename: Takahide
authors.initials: T
authors.lastname: Tsuchiya
authors.forename: Ryuki
authors.initials: R
authors.lastname: Fukuda
authors.forename: Tomomitsu
authors.initials: T
authors.lastname: Hotta
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000134:cerebrospinal fluid*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000134:cerebrospinal fluid*; D001932:Brain Neoplasms / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab